SEATTLE, WA–(Marketwired – May 24, 2017) – CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing United Cannabis Inc.’s (OTCQB: CNAB) progress in initiating clinical trials to study its proprietary Prana Bio Medicinals cannabinoid compounds.
Prana Bio Medicinals
United Cannabis Corp.’s Prana Bio Medicinal products provide patients with a way to mix and match cannabinoids for their therapeutic purposes. Using a patent-pending technology, the company infuses cannabinoids, terpenes, and flavonoids without the use of any heat, solvents, or chemicals to produce 100% natural products. These products interact with the human endocannabinoid system, which has receptors throughout the body and is responsible for homeostasis (the maintenance of a stable internal environment). They are broken down into five color-coded categories and are available as capsules, sublinguals or topicals.
“We pride ourselves on not using any chemical